Showing 15 posts of 127 posts found.

Merck’s Keytruda approved by EC for gastric cancer

August 30, 2023
Research and Development EC, Merck, Oncology, gastric cancer, keytruda

Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …


Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …


NICE recommends MSD’s Keytruda for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

October 22, 2020
Sales and Marketing MSD, NCIE, NHS, keytruda

NICE has moved to recommend the use of MSD’s blockbuster immunotherapy drug Keytruda (pembrolizumab) as a monotherapy in the treatment …


Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer

September 22, 2020
Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma

MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …


New Lenvima/Keytruda combo data in a range of cancers presented at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO2020, Eisai, Lenvima, MSD, keytruda

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster …


MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations

May 29, 2020
Medical Communications, Research and Development Lenvima, keytruda, pharma

MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination …


MSD’s Keytruda hits Phase 3 main goal in first-line colorectal cancer sub-population

April 3, 2020
Medical Communications, Research and Development MSD, colorectal cancer, keytruda, pharma

MSD has lifted the veil on new Phase 3 for its blockbuster immunotherapy Keytruda, showing that the anti-PD-1 therapy met …


Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …


New Keytruda dosing schedule rejected in six cancers by the FDA

February 20, 2020
Sales and Marketing Cancer, FDA, MSD, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda has been stopped in its tracks by the FDA after the US regulator rejected its application …


NICE gives initial ‘no’ to NHS England for kidney cancer drug

February 18, 2020
Manufacturing and Production NHS England, NICE, clinical trials, inlyta, keytruda

The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment …


NICE does not recommend cancer drug combination to the NHS

February 13, 2020
Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …


Seattle Genetics and Astellas unveil positive results for Padcev-Keytruda treatment for bladder cancer

February 12, 2020
Research and Development Astellas, Cancer, Seattle Genentics, bladder, bladder cancer, keytruda, monotherapy

Seattle Genetics and Astellas reported positive results from their trials of Padcev plus Keytruda in treating bladder cancer. The data …

NICE shoots down Keytruda in head and neck cancer over data concerns

January 16, 2020
Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …


MSD’s Keytruda chalks up bladder cancer approval in the US

January 9, 2020
Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …


Bittersweet Phase 3 Keytruda data hits one of two goals in extensive stage small cell lung cancer

January 7, 2020
Manufacturing and Production, Research and Development MSD, keytruda

MSD has lifted the curtain on new Phase 3 data on the efficacy of its blockbuster immunotherapy Keytruda, in combination …

Latest content